- Home
- PFSI vs ITRM Comparison
PFSI vs ITRM Comparison
Compare PFSI & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFSI
- ITRM
- Stock Information
- Founded
- PFSI 2008
- ITRM 2015
- Country
- PFSI United States
- ITRM Ireland
- Employees
- PFSI N/A
- ITRM N/A
- Industry
- PFSI Finance: Consumer Services
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PFSI Finance
- ITRM Health Care
- Exchange
- PFSI Nasdaq
- ITRM Nasdaq
- Market Cap
- PFSI 4.8B
- ITRM 37.7M
- IPO Year
- PFSI 2013
- ITRM 2018
- Fundamental
- Price
- PFSI $97.92
- ITRM $1.21
- Analyst Decision
- PFSI Buy
- ITRM Strong Buy
- Analyst Count
- PFSI 6
- ITRM 1
- Target Price
- PFSI $122.33
- ITRM $5.00
- AVG Volume (30 Days)
- PFSI 521.5K
- ITRM 322.6K
- Earning Date
- PFSI 04-22-2025
- ITRM 05-12-2025
- Dividend Yield
- PFSI 1.24%
- ITRM N/A
- EPS Growth
- PFSI 113.14
- ITRM N/A
- EPS
- PFSI 5.84
- ITRM N/A
- Revenue
- PFSI $2,858,491,000.00
- ITRM N/A
- Revenue This Year
- PFSI N/A
- ITRM N/A
- Revenue Next Year
- PFSI $14.35
- ITRM $150.10
- P/E Ratio
- PFSI $16.56
- ITRM N/A
- Revenue Growth
- PFSI 27.47
- ITRM N/A
- 52 Week Low
- PFSI $83.03
- ITRM $0.81
- 52 Week High
- PFSI $119.13
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- PFSI 52.97
- ITRM 51.88
- Support Level
- PFSI $93.46
- ITRM $1.01
- Resistance Level
- PFSI $97.27
- ITRM $1.16
- Average True Range (ATR)
- PFSI 5.33
- ITRM 0.08
- MACD
- PFSI 0.27
- ITRM 0.01
- Stochastic Oscillator
- PFSI 72.17
- ITRM 80.73
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.